Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 44 % of short-term debt in 2024; threshold 65 %.
Financials
Financial year 2024
PharmaOPS.BXL from Brussel, company number BE0804644494, closed financial year 2024 with a result of € 5,268 after tax. For that financial year PharmaOPS.BXL recorded a gross margin of € 596,330 and equity of € 6,268. Compared with financial year 2023, the result moved from € -7,068 to € 5,268. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2025.
€ 6,268
▲ € 5,268 vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 5,268
▲ still € 7,068 loss in 2023
Profit after tax over the fiscal year.
€ 122,911
▼ 45% vs 2023
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2024. Retained profit grew to € 5,268.
People and assets in 2024
6.1
Average over the fiscal year, from the social balance sheet.
€ 332,933
▲ € 287,321 vs 2023
€ 54,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 9,487
▼ 5% vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2024
€ 2.2 million
▲ 243% vs 2023
€ 200,773 is repaid this year. At this pace the long-term loan is gone in ≈ 11 years.
€ 498,164
▲ € 430,709 vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 51,778
▲ 267% vs 2023
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|
| Gross margin | € 65,148 | € 596,330 | ▲ € 531,182 |
| Profit after taxes | € -7,068 | € 5,268 | ▲ € 12,336 |
| Equity | € 1,000 | € 6,268 | ▲ € 5,268 |
| Total debts | € 986,675 | € 3,553,232 | ▲ 260% |
| Cash | € 224,539 | € 122,911 | ▼ 45% |
| Land & buildings | - | € 17,985 | |
| Retained profit | € 0 | € 5,268 | |
| Bank debt | € 644,517 | € 2,212,257 | ▲ 243% |
| Balance sheet total | € 987,675 | € 3,559,500 | ▲ 260% |
| Employees (FTE) | 0 | 6.1 |
Key figures of PharmaOPS.BXL, fiscal years 2023 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to PharmaOPS.BXL?
What happened at PharmaOPS.BXL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 5,268. filed late Source: NBB ↗
- New establishment in Wemmel. KBO
- New establishment in Brussel. KBO
- New establishment in Ukkel. KBO
- New establishment in Vorst. KBO
- New establishment in Sint-Agatha-Berchem. KBO
- PHARMABXL became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 7,068 loss in 2023 to € 5,268 profit in 2024.
Paid € 550 in corporate taxes since 2023.
Best year ever: 2024, with € 5,268 profit.
On average € 97,800 of value added per employee in 2024.
A new publication or filing at PharmaOPS.BXL? We notify you, reason included.
Follow PharmaOPS.BXLDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind PharmaOPS.BXL is PHARMABXL. PHARMABXL is also behind PharmaPROP.BXL.
Directors
According to the 2024 annual accounts
since 2023
Establishments
Establishment units
Physical locations of this company
Zavelput 17
1000 Brussel
Koekelberglaan 1
1082 Sint-Agatha-Berchem
Active since 17 August 2023
Waterloosesteenweg 795
1180 Ukkel
Active since 2 January 2024
Albertlaan 154
1190 Vorst
Active since 1 October 2023
Kruidtuinlaan 36
1000 Brussel
Active since 1 June 2024
J. De Ridderlaan 54-56
1780 Wemmel
Active since 17 February 2025
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.
All companies at this address →Association d'Entraide homophile - Association pour la Défense des Homophiles
PHARMACIE BOTANIQUE
€ 236,541 gross margin · 2023
PharmaBXL same network
€ 436,169 gross margin · 2024
AMPHIKTION
€ 200,476 gross margin · 2024
PharmaPROP.BXL same network
€ 50,325 gross margin · 2024
+1 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Google Workspace
Hosting
CLOUDFLARESPECTRUM Cloudflare, Inc., US
Website info
Features
Security
Details
- Company number
- 0804.644.494
- VAT number
- BE 0804.644.494
- Registered office
- Zavelput 17, 1000 Brussel
- Names & denominations
- PharmaOPS.BXL
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 17 August 2023
- Peppol
- Active · Active since 6 Mar 2026
- Contact
- pharmabxl.be
- Activities · NACE
Detailhandel in farmaceutische producten
Verhuur en exploitatie van eigen of geleased niet-residentieel onroerend goed, exclusief terreinen
Verhuur en exploitatie van eigen of geleased residentieel onroerend goed, exclusief sociale woningen
Handel in eigen onroerend goed